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Abstract
Dominantly inherited mutations in the leucine-rich repeat kinase 2 gene (LRRK2) are the most common cause of familial
Parkinson’s disease (PD) and have also been identified in individuals with sporadic PD. Although the exact cellular function
of LRRK2 remains unknown, most PD-linked mutations appear to be toxic to cells in culture via mechanisms that depend on
the kinase activity of LRRK2 or on the formation of cytoplasmic inclusions. Here we show that the E3 ubiquitin ligase CHIP
physically associates with LRRK2 and regulates the cellular abundance of LRRK2. We further show that LRRK2 forms a
complex with overexpressed and endogenous CHIP and Hsp90. Our data indicates that the destabilization of LRRK2 by CHIP
is due to ubiquitination and proteasome-dependent degradation. Hsp90 can attenuate CHIP-mediated degradation and this
can be blocked by the Hsp90 inhibitor geldanamycin. These findings provide important insight into the cellular regulation
of LRRK2 stability and may lead to the development of therapeutics to treat PD based on controlling LRRK2 stability.
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Introduction
Parkinson’s disease (PD) is the most common neurodegenerative
movement disorder and affects 1–2% of the population over 60
years old. The primary clinical symptoms have classically been
defined as bradykinesia, resting tremor, cogwheel rigidity and
abnormal gait. Despite intensive research, the cause of PD remains
unknown. Epidemiological studies have failed to definitively
identify a single cause for PD, however, age is the greatest risk
factor and many studies have implicated cumulative oxidative
stress, mitochondrial dysfunction, protein aggregation and neu-
roinflammation in PD pathogenesis or progression [1,2,3,4].
Although PD is generally sporadic, many families are known to
have a Mendelian pattern of inherited parkinsonism. The recent
identification of several genes with mutations linked to familial
forms of PD has provided unprecedented opportunities to discover
potential pathogenic mechanisms and to rationally develop more
effective therapies [5].
Of all the mutations linked to familial PD to date, the G2019S
missense mutation in the leucine-rich repeat kinase 2 gene
(LRRK2) is the most common and can account for a significant
fraction of apparently sporadic PD cases in certain populations
[6,7,8]. LRRK2 is expressed widely throughout the brain and
other tissues, including—but not limited to—the cells most
affected in PD [9,10,11]. The LRRK2 gene codes for a large
protein of 2527 amino acids with multiple domains predicted by
primary sequence homology [12]. The N-terminus is predicted to
contain armadillo (ARM) repeats and ankyrin repeats, followed by
a leucine-rich repeat (LRR) domain, a Ras of complex (Roc)
GTPase domain, a C-terminal of Roc (COR) domain, a tyrosine
kinase domain with greatest sequence similarity to the mixed-
lineage kinase subclass of mitogen-activated protein kinase kinase
kinases (MAPKKKs), followed by a C-terminal WD40 domain.
The recent crystal structure of the ROC domain reveals a dimeric
GTPase structure [13]. In vitro studies have confirmed that
LRRK2 possesses both GTPase and kinase activities, including
autophosphorylation activity and phosphorylation activity towards
generic substrates and potential physiologic substrates
[14,15,16,17,18,19,20,21,22].
Dominantly inherited point mutations that segregate with PD
have been identified in the leucine-rich repeat, ROC GTPase,
COR and kinase domains of LRRK2 [12]. Additional putatively
pathogenic amino acid substitutions have been identified in these
domains and in the ARM and ankyrin repeat regions and the
WD40 domain of LRRK2 [23]. The molecular mechanisms by
which these mutations cause PD remain uncertain. The prevailing
hypothesis is that these mutations either directly or indirectly lead
to increased LRRK2 kinase activity and promote inclusion
formation, which can be neurotoxic [24]. Because point mutations
have been identified throughout the sequence of LRRK2, not just
in the kinase domain, it is likely that intra- and intermolecular
protein-protein interactions both inside and outside the kinase
domain are important for the normal function of LRRK2.
Alterations in protein-protein interactions may be the mechanism
by which some LRRK2 mutations cause disease. Identifying
proteins that interact with LRRK2 is therefore crucial for filling
the current gap in our understanding of the normal function of
LRRK2 and for determining how disease-linked mutations lead to
aberrant LRRK2 function and neurodegeneration.
In an effort to better define the cellular function of LRRK2, we
conducted yeast two-hybrid screens to identify potential LRRK2
interacting proteins. We identified a robust protein-protein
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Interacting Protein), which is an E3 ubiquitin ligase crucial for the
ubiquitination of several heat shock protein (HSP)70/90 client
proteins that are involved in neurodegenerative disease [25]. Our
screen also identified a robust protein-protein interaction between
LRRK2 and Hsp90, which has previously been identified as a
LRRK2 binding protein [18,26,27]. We confirmed both these
interactions by different reporter assays in yeast cells and by co-
immunoprecipation assays in mammalian cells. We further found
that LRRK2 is destabilized by CHIP. The destabilization of
LRRK2 by CHIP is due to CHIP-mediated ubiquitination and
proteasome-dependent degradation. Hsp90 can block CHIP-
mediated degradation and inhibition of Hsp90 restores CHIP-
mediated degradation of LRRK2. These findings reveal potential
cellular mechanisms that regulate LRRK2 abundance, which may
provide therapeutic targets for familial and sporadic PD.
Materials and Methods
Plasmid Constructs
Full-length mouse LRRK2 cDNA was cloned by PCR from
mouse brain cDNA prepared in our lab. Seven putative LRRK2
domains comprising amino acids 1–690 (ARM), 691–1009
(Ankyrin), 1010–1312 (LRR), 1331–1512 (ROC), 1514–1866
(COR), 1869–2128 (kinase) and 2141–2432 (WD40) were
subcloned into pGBKT7 (Clontech) as baits for yeast two-hybrid
analyses and into pMyc-CMV (Clontech) for mammalian cell
transfections, along with full-length LRRK2. Point mutations
(G2019S, R1441C and D1994A) were generated using the
QuickChange Site-Directed Mutagenesis kit (Stratagene). Wild-
type human LRRK2 and LRRK2(R1441C) constructs [28] were
kindly provided by Dr. Mark Cookson. pcDNA-CHIP was kindly
provided by Dr. Cam Patterson. pMT-HA-Ub was kindly
provided by Dr. Pat Gallagher. pcDNA-His6-CHIP(K30A) and
pcDNA-His6-CHIP(H260Q) were kindly provided by Dr. Len
Neckers. pFlag-Hsp90 was kindly provided by Dr. Kapil Bhalla.
pCS2-UbK0 was kindly provided by Dr. Ken Nephew. pHA-
CHIP(K30A) and pHA-CHIP(H260Q) were constructed using
pcDNA-His6-CHIP(K30A) and pcDNA-His6-CHIP(H260Q).
pHA-CHIP, pHA-CHIPDT, pHA-CHIPDU, pHA-TPR and
pHA-TPR(K30A) were constructed in this study by PCR cloning
from pcDNA-CHIP or pcDNA-His6-CHIP(K30A).
Antibodies and Other Reagents
The following antibodies and other reagents were used in these
studies: Mouse monoclonal anti-HA (#MMS-101P Covance,
Emeryville, CA); Mouse monoclonal anti-myc (#GTX20032
GeneTex, San Antonio, TX); Rabbit anti-HA (#ab9110 Abcam,
Cambridge, MA); Rabbit anti-myc (#2272 Cell Signaling
Technology, Danvers, MA); Rat monoclonal anti-Hsp90 (Stress-
gen, Ann Arbor, MI); Mouse anti-b-actin (#AAN02 Cytoskeleton,
Denver, CO); Rabbit anti-CHIP (#PC711 Calbiochem, San
Diego, CA); Mouse anti-Flag (#F3165 Sigma). Mouse anti-
ubiquitin was kindly provided by Dr. Amyn Habib. Rabbit IgG,
Peroxidase-conjugated goat anti-mouse IgG(H+L) and anti-rabbit
IgG(H+L) and anti-rat IgG(H+L) were purchased from Jackson
ImmunoResearch Laboratories. Lipofectamine 2000 (11668–027)
was purchased from Invitrogen (Carlsbad, CA) and complete
protease inhibitor cocktail (11873580001) was purchased from
Roche Molecular Biochemicals (Indianapolis, IN). Geldanamycin
was purchased from Alexis Biochemicals (San Diego, CA).
Lactacystin (70980) was purchased from Cayman Chemical
(Ann Arbor, MI). ImmunoPure Immobilized Protein A/G beads
(20421) were purchased from Pierce (Rockford, IL). X-a-Gal
(MESP-1900) was purchased from Growcells (Irvine, CA). X-b-
Gal (X1001-5) was purchased from Zymo Research (Orange, CA).
Yeast nitrogen base w/o amino acids (291940) and amino acid
Drop-out supplements (DO-Leu, DO-Trp, DO-Leu-Trp, DO-
Leu-Trp-His, DO-Leu-Trp-His-Ade) were from Clontech. 3-AT
(3-amino-1,2,4-triazole) was purchased from Sigma. ON-TAR-
GETplus SMARTpool CHIP siRNA (L-007201-00) and non-
targeting control siRNA (D-001810-02-05) were purchased from
Dharmacon (Lafayette, CO).
Yeast Two-Hybrid Analyses
Bait plasmids consisting of each individual LRRK2 domain in
pGBKT7 (Clontech) were transformed into yeast strain AH109
(MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, gal4D, gal80D,
LYS2::GAL1UAS-GAL1TATA-HIS3, GAL2UAS-GAL2TATA-ADE2, UR-
A3::MEL1UAS-MEL1TATA-lacZ) (Clontech). Yeast clones harboring
the bait plasmids were selected on SD/-Trp medium. Bait
autoactivation was tested on SD/-Trp-His medium. The baits
without or with slight autoactivation were used to screen a mouse
brain cDNA library (Clontech catalog number 638863) pre-
transformed in yeast strain Y187 (MATa, ura3-52, his3-200, ade2-
101, trp1-901, leu2–3, 112, gal4D, met–, gal80D, URA3::GAL1UAS-
GAL1TATA-lacZ) (Clontech). Yeast two-hybrid screens were
performed as previously described [29] using the Matchmaker
GAL4 system (Clontech). Briefly, AH109 yeast cells harboring one
bait plasmid were mated with Y187 cells harboring the Clontech
Matchmaker mouse brain cDNA library. The diploid zygotes
(5610
6) were plated on triple selective medium (SD/-Leu-Trp-His
plus 5 mM 3-AT). The prey plasmids from yeast colonies growing
on the triple selective medium were rescued and sequenced. To
further verify the interactions in yeast cells, the obtained prey
plamsids and their bait plasmid were co-transformed into AH109
yeast cells. After growing up on double selective medium (SD/-
Trp-Leu), the yeast cells were re-streaked onto quadruple selective
medium (SD/-Leu-Trp-His-Ade plus 2 mM 3-AT) and were used
to perform X-a-Gal assays (MEL1 reporter) and X-b-Gal colony-
lift assays (LacZ reporter) according to the Yeast Protocols
Handbook (Clontech).
Cell Transfection
HEK293 cells were maintained in DMEM with 4 mM L-
glutamine, 4.5 g/liter glucose, 10% FBS, 50 U penicillin, 50 mg/
ml streptomycin. Neuroblastoma SH-SY5Y cells were maintained
in DMEM/F12 (1:1) medium with 10% FBS and 50 U penicillin,
50 mg/ml streptomycin. For HEK293 cell transfection, cells (80%
confluence) were transfected with an equal amount of total
plasmid DNA (adjusted with the corresponding empty vector) by
the calcium phosphate method. For siRNA transfection into SH-
SY5Y cells, the cells (40–50% confluence) were transfected with
50 ng of pMyc-LRRK2 and 0–40 picomoles of CHIP siRNA or
control siRNA using Lipofectamine 2000 cell transfection reagent
according to the manufacturer’s instructions.
Immunoprecipitation and Western blot
Twenty-four to sixty hours after cell transfection, the cells were
lysed in 500 ml ice-cold buffer (50 mM Tris pH 7.4, 150 mM
NaCl, 1% NP-40, 16Roche complete protease inhibitor cocktail).
The cell lysates were incubated on ice for 30 min and centrifuged
at 12,000g for 10 min at 4uC. The supernatants were pre-cleared
at 4uC for 1 h with 10 ml of ImmunoPure Immobilized Protein A/
G beads. Rabbit polyclonal antibody (anti-myc or anti-HA) was
added to the pre-cleared supernatants at 1:500 dilution and
incubated at 4uC for 2 h. 20 ml of ImmunoPure Immobilized
Protein A/G beads was added and incubated for another 1 h. The
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protease inhibitor cocktail. Proteins were eluted from the beads by
heating at 95uCi n1 6 Laemmli buffer, resolved on 4–20%
gradient gels (BioRad), transferred to nitrocellulose and detected
by western blot using mouse monoclonal anti-HA or anti-myc
antibodies, HRP-conjugated goat anti-mouse secondary antibodies
(Jackson Immunoresearch) and chemiluminescent detection
(Pierce).
Ubiquitination Assay
pMyc-LRRK2, pcDNA-CHIP and pMT-HA-Ub were co-
transfected into HEK293 cells. After incubation for 24 h,
immunoprecipitation was performed using a rabbit polyclonal
anti-myc antibody. Mouse monoclonal anti-ubiquitin antibody
was used to detect the ubiquitination of LRRK2. Monoclonal anti-
myc antibody was used to probe LRRK2 expression.
Results
Identification of Hsp90 and CHIP as LRRK2 interacting
proteins
We used each individual domain of LRRK2 as baits for yeast
two-hybrid analyses to identify potential interacting proteins. Our
screens of a mouse brain cDNA library yielded clones showing
robust protein-protein interactions in yeast cells with the ARM
domain and the ROC domain of LRRK2. DNA sequencing
revealed that the interactor of the ARM domain corresponded to
the C-terminal portion of heat shock protein 90 (Hsp90) from
amino acid 248 to amino acid 704 (designated here as Hsp90248-
stop) and the interactor of the ROC domain corresponded to the
charged domain of the E3 ubiquitin ligase CHIP from amino acid
150 to amino acid 200 (designated here as CHIP150–200). To
confirm these protein-protein interactions in mammalian cells, the
LRRK2 ARM and ROC domains and their interactors
(Hsp90248–stop and CHIP150–200) were cloned into mammalian
cell expression vectors with N-terminal myc or HA epitope tags
(pMyc-CMV and pHA-CMV). Full-length LRRK2 and CHIP
were also cloned into these vectors for mammalian cell expression.
Co-transfection of HEK293 cells followed by immunoprecipitation
and western blotting showed that the ROC domain of LRRK2
robustly co-immunoprecipated with CHIP150–200 (Figure 1A, right
lane), and the ARM domain of LRRK2 co-immunoprecipitated
with Hsp90248–stop (Figure 1B, right lane). Full-length LRRK2 also
co-immunoprecipitated with full-length CHIP and full-length
Hsp90 (Figure 1C, D, right lane of each panel). All of these
interactions were detected both by immunoprecipitating myc-
tagged LRRK2 (or myc-LRRK2 domain) and western blotting
HA-tagged interactors and by immunoprecipitating HA-tagged
interactors and western blotting myc-tagged LRRK2 (or myc-
LRRK2 domain). Control immunoprecipitations from cells
transfected with equivalent amounts of empty CMV expression
vectors (pMyc-CMV or pHA-CMV) confirmed the absence of
non-specific binding to the immunoprecipitation antibodies or
protein A/G beads. Direct western blotting of the cell lysates
indicated that the immunoprecipitation results were not due to
differences in protein expression levels or transfection efficiencies
(Figure 1A–D, left two lanes of each panel).
CHIP interacts with LRRK2 through its TPR and charged
domains
Because both CHIP and LRRK2 have multiple domains (see
Supplemental Figure S1), we sought to further delineate which
domains of CHIP are critical for interacting with different regions
of LRRK2. To determine whether full-length CHIP could bind to
different regions of LRRK2, we co-transfected HEK293 cells with
an expression vector for HA-tagged full-length CHIP (pHA-CHIP)
and expression vectors coding for either myc-tagged ARM-ANK-
LRR domains of LRRK2 (pMyc-AAL) or myc-tagged ROC-
COR-kinase-WD40 domains of LRRK2 (pMyc-RCKW) (see
Supplemental Figure S1). Surprisingly, full length CHIP co-
immunoprecipitated with both the ARM-ANK-LRR domains of
LRRK2 (Figure 2A) and the ROC-COR-kinase-WD40 domains
of LRRK2 (Figure 2B).
The primary sequence and crystal structures of CHIP show
three domains: an N-terminal tetratricopeptide repeat (TPR)
domain, a C-terminal U-box domain and an intervening charged
domain [30,31] (see Supplemental Figure S1). U-box domains are
structurally related to RING finger domains, both of which confer
E3 ubiquitin ligase activity. Because LRRK2 has previously been
shown to bind to the E3 ubiquitin ligase Parkin via its second
RING finger domain [32], we hypothesized that the U-box
domain of CHIP was responsible for binding to LRRK2. To test
whether the U-box domain of CHIP is critical for binding to either
half of LRRK2, we co-transfected HEK293 cells with an
expression vector for HA-tagged CHIP lacking only the U-box
domain (pHA-CHIPDU) and expression vectors coding for either
myc-tagged ARM-ANK-LRR domains of LRRK2 (pMyc-AAL)
or myc-tagged ROC-COR-kinase-WD40 domains of LRRK2
(pMyc-RCKW). Unexpectedly, the U-box domain of CHIP is
apparently dispensable for binding to either half of LRRK2
because HA-CHIPDU co-immunoprecipitated with both the
ARM-ANK-LRR domains of LRRK2 (Figure 2C) and the
ROC-COR-kinase-WD40 domains of LRRK2 (Figure 2D).
The N-terminal TPR domain of CHIP has been shown to
specifically bind to several chaperones such as Hsp70 and Hsp90
[33,34]. Hsp90 has previously been reported to bind to LRRK2
[18,26,27] and we have validated this interaction here (Figure 1B,
D). This raises the possibility that the CHIP TPR domain binds to
LRRK2 indirectly, via Hsp90. To determine whether the TPR
domain is necessary for CHIP to interact with either half of
LRRK2, we co-transfected HEK293 cells with an expression
vector for HA-tagged CHIP lacking only the TPR domain (pHA-
CHIPDT) and expression vectors coding for either myc-tagged
ARM-ANK-LRR domains of LRRK2 (pMyc-AAL) or myc-
tagged ROC-COR-kinase-WD40 domains of LRRK2 (pMyc-
RCKW). Deletion of the CHIP TPR domain completely abolished
the interaction between CHIP and the ARM-ANK-LRR domains
of LRRK2 based on the absence of co-immunoprecipitation
(Figure 2E). By contrast, deletion of the CHIP TPR domain did
not disrupt the interaction between CHIP and the ROC-COR-
kinase-WD40 domains of LRRK2 because these domains robustly
co-immunoprecipitated with CHIPDT (Figure 2F).
These results, together with our data showing that Hsp90 binds
to the ARM domain of LRRK2 (Figure 1B), led us to hypothesize
that CHIP binds to the N-terminus of LRRK2 indirectly via
Hsp90, which is well-known to bind to the TPR domain of CHIP
[35]. Hsp90 is an ATP-dependent molecular chaperone that can
be inhibited by compounds such as geldanamycin, which binds to
the conserved N-terminal ATP binding pocket and blocks
conformational changes required for molecular chaperone func-
tion [36]. To test the hypothesis that Hsp90 function is required
for CHIP to bind to the N-terminus of LRRK2, we co-transfected
HEK293 cells with an expression vector for HA-tagged full-length
CHIP (pHA-CHIP) and expression vectors coding for either myc-
tagged ARM-ANK-LRR domains of LRRK2 (pMyc-AAL) or
myc-tagged ROC-COR-kinase-WD40 domains of LRRK2
(pMyc-RCKW) and incubated the cells with 1 mM geldanamycin
for 1 hour prior to cell collection to block Hsp90 function. In
CHIP Regulates LRRK2 Stability
PLoS ONE | www.plosone.org 3 June 2009 | Volume 4 | Issue 6 | e5949contrast to the robust co-immunoprecipitation in the absence of
geldanamycin (Figure 2A), full-length CHIP did not co-immuno-
precipitate with the myc-tagged ARM-ANK-LRR domains of
LRRK2 in the presence of geldanamycin (Figure 2G), indicating
that Hsp90 function is required for CHIP to bind to the N-
terminal portion of LRRK2. By contrast, geldanamycin did not
prevent full-length CHIP binding to myc-tagged ROC-COR-
kinase-WD40 domains of LRRK2 (Figure 2H). Together with the
data shown in Figure 2F, this suggests that neither the TPR
domain of CHIP nor Hsp90 are required for CHIP to bind to the
C-terminal portion of LRRK2. Because the U-box domain of
CHIP is also dispensable (Figure 2D), the intervening charged
domain of CHIP appears to be sufficient for CHIP to interact with
the C-terminal portion of LRRK2. This is consistent with our
yeast two-hybrid screen results and with the data in Figure 1A,
which shows that the intervening charged domain of CHIP binds
to the ROC domain of LRRK2.
The above data shows that the TPR domain of CHIP is
required for CHIP to bind to the N-terminal portion of LRRK2.
To test whether isolated TPR domain is sufficient for binding to
LRRK2, we co-transfected HEK293 cells with HA-tagged TPR
domain and Myc-tagged N-terminal or C-terminal portions of
LRRK2. Co-immunoprecipitation assays showed that isolated
CHIP TPR domain binds to the ARM-ANK-LRR domains of
LRRK2 but not to the ROC-COR-kinase-WD40 domains of
LRRK2 (Supplemental Figure S2A, B). The K30A point mutation
within the TPR domain of CHIP that blocks CHIP binding to
Hsp90 [37] also blocks binding of the isolated TPR domain to the
N-terminus of LRRK2 (Supplemental Figure S2C, D). We further
found that isolated CHIP TPR domain binds to full length
LRRK2 (Supplemental Figure S2E) and that this was blocked by
the K30A point mutation (Supplemental Figure S2F). Consistent
with the above data, full length CHIP with the K30A point
mutation fails to bind to the ARM-ANK-LRR domains of
Figure 1. Co-immunoprecipitation of partial and full-length LRRK2, CHIP and Hsp90. The indicated myc- and HA-epitope tagged
constructs (0.5 mg for each) were co-transfected into 4.5610
6 HEK293 cells in 60 mm dishes. Lactacystin was added to the medium at a final
concentration of 5 mM to prevent CHIP-mediated degradation of LRRK2. HEK293 cell lysates were subjected to immunoprecipitation using polyclonal
anti-myc or anti-HA antibodies, then immunoblotted using monoclonal anti-HA or anti-myc antibodies, respectively. Cell lysates were also directly
immunoblotted using monoclonal anti-HA and anti-myc antibodies to verify similar protein expression levels in experimental and empty expression
vector (CMV) control transfections. (A) The ROC domain of LRRK2 co-immunoprecipitates with its interactor identified from the yeast two-hybrid
screen, CHIP150–200. (B) The ARM domain of LRRK2 co-immunoprecipitates with its interactor identified from the yeast two-hybrid screen, Hsp90248–stop.
(C) Full-length LRRK2 co-immunoprecipitates with full-length CHIP. (D) Full-length LRRK2 co-immunoprecipitates with full-length Hsp90.
doi:10.1371/journal.pone.0005949.g001
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mutation does not block binding of full length CHIP to the ROC-
COR-kinase-WD40 domains of LRRK2 (Supplemental Figure
S2H) or to full length LRRK2 (data not shown). Likewise,
geldanamycin does not block binding of full length wild-type
CHIP to full length LRRK2 (Supplemental Figure S3).
CHIP regulates LRRK2 stability
Because CHIP has been shown to regulate cellular levels of
other proteins linked to neurodegenerative disease, such as
phospho-tau [38], we investigated the effect of CHIP overexpres-
sion on levels of LRRK2. We transiently co-transfected HEK293
cells with a fixed amount of myc-tagged full-length LRRK2 and
increasing amounts of full-length CHIP, plus empty vector to
normalize all transfections for total DNA. Western analysis of cells
harvested 48 hours after transfection showed that overexpression
of CHIP decreased LRRK2 levels in a dose-dependent manner
(Figure 3A, upper panel). CHIP overexpression had no effect on
the levels of endogenous Hsp90 or b-actin (Figure 3A, middle
panels). Stripping and re-blotting with an anti-CHIP antibody
confirmed the increasing amount of CHIP protein in cells
transfected with increasing amounts of CHIP expression vector
(Figure 3A, bottom panel). This indicates that CHIP can regulate
the stability of LRRK2.
Because we identified CHIP interactions with both N-terminal
and C-terminal portions of LRRK2 (Figure 2), we sought to
determine whether one or both of these interactions are
responsible for destabilization of LRRK2 by CHIP. We transiently
co-transfected HEK293 cells with fixed amounts of myc-tagged
fragments of LRRK2 and increasing amounts of full-length CHIP,
plus empty vector to normalize all transfections for total DNA.
Western analysis 48 hours after transfection showed that overex-
pression of CHIP decreased levels of both myc-tagged ARM-
ANK-LRR domains of LRRK2 (pMyc-AAL) and myc-tagged
ROC-COR-kinase-WD40 domains of LRRK2 (pMyc-RCKW) in
a dose-dependent manner (Figure 3B). To rule out non-specific
down-regulation of the AAL or RCKW portions of LRRK2,
isolated leucine rich repeat domain (pMyc-LRR) and kinase
domain (pMyc-kinase) of LRRK2 were similarly co-transfected
with increasing amounts of CHIP. These domains were not
significantly down-regulated by CHIP (Figure 3B).
CHIP destabilizes wild-type and mutant LRRK2
To date, several missense mutations in LRRK2 have been linked
to autosomal dominantly inherited PD (e.g. R1441C/G, Y1699C,
G2019S, I2020T), and many additional LRRK2 variants are being
evaluated for conclusive pathogenicity or increased risk for PD [23].
We therefore investigated whether CHIP-mediated degradation of
LRRK2 is affected by LRRK2 point mutations that segregate with
PD or that ablate the kinase activity of LRRK2. We transfected
HEK293 cells with equal amounts of wild-type LRRK2, two PD
pathogenic mutants (G2019S, R1441C) or an artificial kinase dead
variant of LRRK2 (D1994A) [21] and increasing amounts of CHIP
expression vector. Even in the absence of exogenous CHIP
(Figure 3C, left lane of each panel), the cellular levels of wild-type
and mutant LRRK2 differ considerably in transiently transfected
HEK293 cells. The G2019S mutation did not affect LRRK2 levels,
but the R1441C mutation diminished LRRK2 levels slightly
compared to wild-type. The abundance of the artificial kinase-
inactive mutant (D1994A) was significantly decreased relative to
wild-type LRRK2, suggesting that the kinase activity of LRRK2 is
importantforstabilizingLRRK2.Inallcases,increasingamountsof
CHIP expression vector markedly diminished the abundance of
wild-type and mutant LRRK2 relative to b-actin (Figure 3C),
indicatingthatCHIPcandestabilizewild-typeandmutantLRRK2.
To confirm that none of these LRRK2 mutations disrupt CHIP
binding to LRRK2, we conducted co-immunoprecipitation assays
using HEK293 cells co-transfected with CHIP and wild-type or
mutant LRRK2. Wild-type, D1994A, R1441C and G2019S
LRRK2 all co-immunoprecipitated with CHIP (Supplemental
Figure S4), indicating that they are able to bind to CHIP either
directly or indirectly via common adaptor proteins.
Both the TPR and U-box domains are essential for CHIP-
mediated LRRK2 degradation
Because we found that the N-terminal chaperone interaction
(TPR) domain of CHIP and the C-terminal U-box domain of
CHIP are not essential for binding to LRRK2 (Figure 2), we
examined whether these domains of CHIP are required for CHIP-
mediated LRRK2 degradation. To test this, we co-transfected
HEK293 cells with Myc-LRRK2 and HA-CHIP or one of the
following CHIP mutant constructs: 1) a TPR domain point mutant
CHIP(K30A) or TPR domain deletion mutant (CHIPDT), both of
which are unable to interact with Hsp/Hsc70 or Hsp90; and 2) a
U-box domain point mutant CHIP(H260Q) or U-box domain
deletion mutant (CHIPDU), both of which are unable to catalyze
protein ubiquitin conjugation [37]. Western analysis of cell lysates
with anti-myc and anti-HA showed that all the constructs
expressed similar amounts of protein (Figure 4). In contrast to
wild-type CHIP, which degraded LRRK2, none of the CHIP
mutants decreased LRRK2 protein levels (Figure 4). These results
indicate that both the chaperone interaction and the ubiquitin
ligase activity of CHIP are required for CHIP-mediated
degradation of LRRK2 protein.
CHIP can ubiquitinate LRRK2
To determine whether CHIP can ubiquitinate LRRK2,
mammalian expression vectors for myc-tagged LRRK2, CHIP
and HA-tagged ubiquitin (HA-Ub), were co-transfected into
Figure 2. CHIP binds to multiple domains of LRRK2 by different mechanisms. The indicated constructs (0.5 mg for each) were co-
transfected into 4.5610
6 HEK293 cells in 60 mm dishes. Lactacystin was added to the medium at a final concentration of 5 mM to prevent CHIP-
mediated degradation of LRRK2. HEK293 cell lysates were subjected to immunoprecipitation using polyclonal anti-myc or anti-HA antibodies, then
immunoblotted using monoclonal anti-HA or anti-myc antibodies, respectively. Cell lysates were also directly immunoblotted using monoclonal anti-
HA and anti-myc antibodies to verify similar protein expression levels in experimental and empty expression vector (CMV) control transfections. (A)
Co-immunoprecipitation of full-length CHIP and the ARM-Ankyrin-LRR (AAL) portion of LRRK2; (B) Co-immunoprecipitation of full-length CHIP and
the ROC-COR-Kinase-WD40 (RCKW) portion of LRRK2; (C) Co-immunoprecipitation of CHIP lacking the U-box domain (CHIPDU) and the ARM-Ankyrin-
LRR (AAL) portion of LRRK2; (D) Co-immunoprecipitation of CHIP lacking the U-box domain (CHIPDU) and the ROC-COR-Kinase-WD40 (RCKW) portion
of LRRK2; (E) Absence of co-immunoprecipitation of CHIP lacking the TPR domain (CHIPDT) and the ARM-Ankyrin-LRR (AAL) portion of LRRK2; (F) Co-
immunoprecipitation of CHIP lacking the TPR domain (CHIPDT) and the ROC-COR-Kinase-WD40 (RCKW) portion of LRRK2; (G) Geldanamycin impairs
the interaction of full-length CHIP with the ARM-Ankyrin-LRR (AAL) portion of LRRK2; (H) Geldanamycin does not disrupt the interaction of full-length
CHIP and the ROC-COR-Kinase-WD40 (RCKW) portion of LRRK2. For (G-H), geldanamycin was added into the medium to 1 mM final concentration and
incubated for 1 hour prior to cell collection.
doi:10.1371/journal.pone.0005949.g002
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PLoS ONE | www.plosone.org 7 June 2009 | Volume 4 | Issue 6 | e5949HEK293 cells and incubated for 24 hours. Cell lysates were
immunoprecipitated with anti-myc antibody and ubiquitinated
LRRK2 was detected by immunoblotting with anti-ubiquitin
antibody (Figure 5A, upper panel). Cells transfected with all 3
constructs produced typical high-molecular-weight species consis-
tent with polyubiquitinated LRRK2. Incubation of transfected
cells with a proteasome inhibitor, lactacystin, caused the
accumulation of polyubiquitinated LRRK2 as determined by the
increased intensity of the ubiquitin-immunoreactive smear. The
transfections lacking LRRK2 or ubiquitin resulted in no signal.
Cells transfected with LRRK2 and ubiquitin without CHIP
resulted in very weak ubiquitination of LRRK2, perhaps mediated
Figure 4. Both TPR and U-box domain are required for LRRK2 degradation. 1 mg of pMyc-LRRK2 and 0.5 mg of pHA-CMV (Lane 1 from left
to right) or pHA-CHIP (Lane 2) or pHA-CHIP(K30A) (Lane 3) or pHA-CHIP(H260Q) (Lane 4) or pHA-CHIPDU (Lane 5) or pHA-CHIPDT (Lane 6) were co-
transfected into 1.5610
6 HEK293 cells in 35 mm dishes. 48 hours after transfection, cells were harvested and the lysates were immunoblotted with
anti-myc (upper panel), anti-b-actin (middle panel) and anti-HA (lower panel).
doi:10.1371/journal.pone.0005949.g004
Figure 3. CHIP promotes LRRK2 degradation. (A) CHIP promotes full-length LRRK2 degradation. 1.0 mg of pMyc-LRRK2 was co-transfected with
0, 0.1 0.4, 0.6 or 1.0 mg of pHA-CHIP into 1.5610
6 HEK293 cells in 35 mm dishes. Empty vector pHA-CMV was used to normalize the total amount of
DNA for each transfection. After 48-hour incubation, equal amounts of cell lysates were used for immunoblotting using anti-myc antibody and the
membrane was re-probed using anti-Hsp90, anti-CHIP and anti-b-actin antibodies. (B) Effects of CHIP on the stability of N- and C-terminal portions of
LRRK2. 1.0 mg of pMyc-AAL (ARM-Ankyrin-LRR, the N-terminal portion of LRRK2) or pMyc-RCKW (ROC-COR-Kinase-WD40, the C-terminal portion of
LRRK2) were co-transfected with 0, 0.5 or 1.0 mg of pHA-CHIP into 1.5610
6 HEK293 cells in 35 mm dishes. Empty vector pHA-CMV was used to
normalize the total amount of DNA for each transfection. After 48-hour incubation, equal of amounts of cell lysates were used for immunoblotting
using anti-myc antibody (the upper panel for each construct). Membranes were stripped and re-probed using anti-b-actin antibody to confirm equal
loading. To rule out non-specific down-regulation of the AAL or RCKW portions of LRRK2, isolated leucine rich repeat domain (pMyc-LRR) and kinase
domain (pMyc-kinase) of LRRK2 were similarly co-transfected with increasing amounts of CHIP. These domains were not significantly down-regulated
by CHIP. NS, non-specific immunoreactive band above the Myc-tagged kinase domain. (C) CHIP destabilizes wild-type and mutant LRRK2. 1 mgo f
pMyc-LRRK2, LRRK2(G2019S), LRRK2(R1441C) or LRRK2(D1994A) was co-transfected with 0, 0.1, 0.5 or 1.0 mg of pHA-CHIP into 1.5610
6 HEK293 cells in
35 mm dishes. Empty vector pHA-CMV was used to normalize the amount of total DNA for each transfection. After 48-hour incubation, the cells were
harvested and lysates were immunoblotted with anti-myc and anti-b-actin antibodies to measure the abundance of wild-type and mutant LRRK2.
doi:10.1371/journal.pone.0005949.g003
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of the corresponding cell lysates (without immunoprecipitation)
showed that the abundance of LRRK2 was diminished by CHIP
and that lactacystin could inhibit this (Figure 5A, middle panel).
These results demonstrate the ability of CHIP to ubiquitinate
LRRK2.
CHIP down-regulates LRRK2 levels through the ubiquitin
proteasome pathway
To further investigate the extent to which proteasome activity is
required for CHIP-mediated LRRK2 degradation, HEK293 cells
were co-transfected with pHA-CHIP and pMyc-LRRK2, treated
with the proteasome inhibitor lactacystin at concentrations
ranging from 0.1 to 5 mM, and immunoblotted to measure the
abundance of LRRK2 normalized to actin. As shown in Figure 5B,
we observed a lactacystin dose-dependent increase in LRRK2
abundance in cells transfected with both LRRK2 and CHIP.
Treatment with 5 mM lactacystin almost completely blocked
CHIP-mediated degradation of LRRK2 under conditions in
which LRRK2 is almost completely degraded without lactacystin.
By contrast, in cells not transfected with CHIP, lactacystin had
little effect on LRRK2 abundance. To investigate the kinetics of
this effect, we co-transfected HEK293 cells with pMyc-LRRK2
and pHA-CHIP for 24 hours, then added lactacystin to a final
concentration of 5 mM and harvested cells 0, 6, 12, 24 and
36 hours after addition of lactacystin. Western analysis showed
that up to 36 hours is required for LRRK2 to accumulate in the
presence of CHIP and 5 mM lactacystin (Figure 5C). To test
whether polyubiquitination is required for CHIP-mediated
LRRK2 degradation, we co-transfected HEK293 cells with an
artificial ubiquitin variant, UbK0, in which all lysines were
replaced by arginines to prevent polyubiquitination [39]. Expres-
sion of UbK0, but not wild-type ubiquitin, blocked CHIP-
mediated degradation of LRRK2 (Figure 5D), indicating that
CHIP stimulates LRRK2 degradation through the ubiquitin
proteasome pathway, which requires polyubiquitination.
Hsp90 overexpression stabilizes LRRK2 and prevents
CHIP-mediated LRRK2 degradation
It has previously been reported that inhibition of Hsp90 can
destabilize mouse LRRK2 [27]. To examine whether Hsp90
overexpression can stabilize LRRK2 even in the presence of
CHIP, we co-transfected pMyc-LRRK2, pHA-CHIP and increas-
ing amounts of pFlag-Hsp90 into HEK293 cells. The results
indicated that LRRK2 steady-state abundance was increased by
overexpressing Hsp90, even in the presence of CHIP (Figure 6A).
As expected, inhibition of endogenous Hsp90 with geldanamycin
promoted LRRK2 degradation in the presence of CHIP, however,
the effect of geldanamycin could be blocked by lactacystin
(Figure 6B). Together, these data suggest that Hsp90 prevents
CHIP-mediated degradation of LRRK2 via the ubiquitin protea-
some pathway.
LRRK2 forms a protein complex with endogenous CHIP
and Hsp90
Given the data presented here, we sought to determine whether
LRRK2 forms a protein complex with endogenous CHIP and
Hsp90. First, we co-transfected HEK293 cells with pMyc-
LRRK2, pFlag-Hsp90 and pHA-CHIP and immunoprecipitated
the cell lysates with an anti-myc antibody. As expected, CHIP and
Hsp90 were robustly detected by western blotting the immuno-
precipitants with anti-HA and anti-Flag antibodies, respectively
(Figure 7A). Control immunoprecipitation with IgG verified the
absence of non-specific binding. Next, we transfected HEK293
cells with only pMyc-LRRK2, immunoprecipitated the cell lysates
with anti-myc antibody and blotted with anti-CHIP and anti-
Hsp90 antibodies to detect endogenous CHIP and Hsp90 binding
to LRRK2 (Figure 7B). Together, the data show that both
overexpressed and endogenous CHIP and Hsp90 can form a
protein complex with LRRK2.
CHIP siRNA decreases endogenous CHIP and increases
LRRK2 abundance
Because endogenous CHIP forms a complex with LRRK2, we
tested whether decreasing endogenous CHIP by siRNA would
affect LRRK2 abundance. We co-transfected HEK293 cells with
50 ng of pMyc-LRRK2 and 0–40 picomoles of CHIP siRNA and
then used western blot to measure levels of Myc-tagged LRRK2,
endogenous CHIP and b-actin. CHIP siRNA decreased endog-
enous CHIP and increased LRRK2 abundance in a dose
dependent manner (Supplemental Figure S5). Parallel cells
transfected with a non-targeting control siRNA showed no effect
of control siRNA on CHIP or LRRK2 abundance (Supplemental
Figure S5).
Discussion
Here we report the identification of CHIP as a LRRK2
interacting protein and provide evidence that CHIP can
significantly reduce the cellular levels of LRRK2 by ubiquitination
and proteasome-dependent degradation. Our data reveal which
domains of CHIP and LRRK2 are required or dispensable for this
interaction. Surprisingly, we found that CHIP can bind to LRRK2
at least two independent ways. The combined data shown in
Figure 1 and Figure 2 indicate that the charged domain of CHIP
binds to the ROC domain of LRRK2 and that the TPR domain of
CHIP is required for binding to the N-terminal region of LRRK2
that includes the armadillo, ankyrin and leucine-rich repeats. This
is the first demonstration that the charged domain of CHIP
directly binds to another protein. The TPR domain of CHIP
apparently binds to the N-terminal region of LRRK2 indirectly
Figure 5. CHIP can ubiquitinate LRRK2 and promote LRRK2 degradation through the ubiquitin proteasome pathway. (A) From Lane 1
to Lane 6 (from left to right), the indicated constructs were co-transfected into 1.5610
6 HEK293 cells in 35 mm dishes. In Lane 3, lactacystin was
added into the medium to a final concentration of 5 mM immediately following cell transfection. After 24-hour incubation, the cell lysates were
immunoprecipitated using a polyclonal anti-myc antibody. The immunoprecipitants were immunoblotted with monoclonal anti-UB antibody (upper
panel). The corresponding cell lysates were probed using anti-myc and anti-b-actin (middle and lower panels). (B) 1.0 mg of pMyc-LRRK2 was co-
transfected with 0.5 mg pHA-CMV or 0.5 mg of pHA-CHIP into 1.5610
6 HEK293 cells in 35 mm dishes. After 24 hours, lactacystin was added to the
indicated concentration. DMSO was added in Lane 1 as a negative control. The cells were cultured for another 24 hours. The cell lysates were probed
using anti-myc and anti-b-actin. (C) 1.0 pMyc-LRRK2 and 0.5 g of pHA-CHIP were co-transfected into HEK293 cells. After 24 hours, lactacystin was
added to the final concentration at 5 mM. The cells were sampled at 0, 6, 12, 24 and 36 hours after addition of lactacystin. The cell lysates were
probed using anti-myc and anti-b-actin. (D) HEK293 cells were transfected with 1.0 mg pMyc-LRRK2, with or without 250 ng pHA-CHIP, pMT-HA-Ub, or
pCS2-UbK0, as indicated. 48 hours after transfection, LRRK2 protein levels were determined by immunoblotting with anti-myc antibody.
doi:10.1371/journal.pone.0005949.g005
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[35], because blocking Hsp90 function with geldanamycin
completely prevented the binding of full-length CHIP to the N-
terminal region of LRRK2. By contrast, geldanamycin did not
prevent the binding of full-length CHIP to the C-terminal half of
LRRK2 (Figure 2), indicating that the interaction between the
charged domain of CHIP and the ROC domain of LRRK2 does
not require Hsp90 function. We further show that the isolated
TPR domain of CHIP is sufficient for binding to the N-terminal
half of LRRK2, but not to the C-terminal half of LRRK2
(Supplemental Figure S2). Consistent with the geldanamycin data,
the K30A point mutation within the TPR domain that blocks
CHIP binding to Hsp90, also blocks binding to the N-terminal half
of LRRK2 (Supplemental Figure S2).
We propose a model in which the charged domain of CHIP
binds to the ROC domain of LRRK2 either directly or indirectly,
but independent of Hsp90, while the TPR domain of CHIP binds
to the N-terminus of LRRK2 indirectly, via Hsp90 (Figure 7C).
Surprisingly, the U-box domain of CHIP, which is structurally
related to RING finger ubiquitin ligase domains, is apparently
dispensable for CHIP binding to LRRK2 (Figure 2C, D). This
mode of binding differs from the previous finding that LRRK2
binds to the second RING finger domain of the E3 ubiquitin ligase
Parkin [32]. LRRK2 reportedly enhances the auto-ubiquitination
activity of Parkin, however, Parkin does not ubiquitinate LRRK2
[32]. By contrast, our data indicates that CHIP ubiquitinates
LRRK2 (Figure 5). Because CHIP has also been reported to form
a complex with Parkin and to enhance the ubiquitin ligase activity
of Parkin [40], it is possible that the reported interaction between
LRRK2 and Parkin is mediated by CHIP.
Our most striking finding is that CHIP decreased the stability of
LRRK2 in a dose-dependent manner (Figure 3). Because we
found that CHIP can bind directly to LRRK2 and cause the
ubiquitination and proteasome-dependent degradation of
LRRK2, this is a likely mechanism by which CHIP destabilizes
LRRK2. CHIP-mediated degradation of LRRK2 appears to
require the chaperone interaction function of CHIP because we
did not observe any LRRK2 destabilization by a TPR domain
point mutant of CHIP (K30A) or by a TPR domain deletion
mutant of CHIP (CHIPDT), both of which are unable to interact
with Hsp/Hsc70 or Hsp90 [37]. CHIP-mediated degradation of
LRRK2 appears to also require the ubiquitin ligase activity of
CHIP because we did not observe any LRRK2 destabilization by
a U-box domain point mutant of CHIP (H260Q) or by a U-box
domain deletion mutant of CHIP (CHIPDU), both of which are
unable to catalyze protein ubiquitin conjugation [37].
Figure 6. Hsp90 can attenuate CHIP-mediated LRRK2 degradation. (A) 1.0 mg pMyc-LRRK2 and 0.5 mg pHA-CHIP were co-transfected with 0,
0.1, 0.4, 0.6, 1.0 mg pFlag-Hsp90. After 48-hour incubation, the cell lysates were immunoblotted with anti-myc and anti-b-actin antibodies. (B) 1.0 mg
of pMyc-LRRK2 was co-transfected with 0.5 pHA-CMV (Lane 1 and 2 from left to right) or 0.5 mg pHA-CHIP (Lane 3–8). 24 hours after cell transfection,
GA and lactacystin were added to the indicated concentrations and the cells were cultured for another 24 hours prior to cell collection and western
analysis.
doi:10.1371/journal.pone.0005949.g006
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wild-type LRRK2 and LRRK2 with disease-linked point muta-
tions (Figure 3C), therefore the pathogenic mechanisms of the
mutations we tested do not likely involve diminished CHIP-
mediated degradation. These findings are consistent with previous
studies that found no effect of LRRK2 mutations on ubiquitina-
tion, proteasomal degradation, steady-state levels or turnover of
LRRK2 [19,27]. However, we found that the kinase activity of
LRRK2 is important for stabilizing cellular levels of LRRK2
because an artificial variant of LRRK2 lacking kinase activity was
markedly and consistently destabilized even in the absence of
exogenous CHIP (Figure 3C). The diminished abundance of
R1441C and D1994A LRRK2 in the absence of exogenous CHIP
could be due to degradation mediated by endogenous CHIP, other
degradation mechanisms or to other possible effects such as altered
expression. LRRK2 kinase activity does not appear to be required
for CHIP mediated-degradation because CHIP decreased the
abundance of the artificial kinase-inactive mutant (D1994A)
LRRK2 in a dose-dependent manner (Figure 3C), although this
experiment cannot rule out the possibility that CHIP affects
expression rather than degradation.
CHIP has previously been shown to promote the proteasomal
degradation of other proteins implicated in neurodegenerative
diseases such as tau, Ab, a-synuclein oligomers and proteins with
expanded polyglutamine repeats [34,41,42,43,44,45,46,47,48].
During revision of this manuscript, Ko et al. reported that CHIP
regulates LRRK2 ubiquitination, degradation and toxicity [49].
Similar to our findings, Ko et al. found that CHIP binds to both
wild-type and mutant LRRK2 and promotes the ubiquitination
and proteasomal degradation of LRRK2. Our findings differ in
that we identified two independent means of CHIP binding to
LRRK2: an indirect interaction between the TPR domain of
CHIP and the ARM domain of LRRK2, likely via Hsp90, and an
interaction between the charged domain of CHIP and the ROC
domain of LRRK2, which is either direct or indirect via a
common adaptor protein. The ARM domain interaction may not
have been detected by Ko et al. because the isolated full length
ARM domain was not shown to be tested for CHIP binding.
In addition to CHIP, our yeast two-hybrid analysis also identified
Hsp90 as a LRRK2 binding protein. Several previous studies have
shown that Hsp90 can bind to full length LRRK2 or to the kinase
domain of LRRK2 [18,26,27]. Here we show for the first time that
Figure 7. LRRK2, CHIP and Hsp90 form a protein complex. (A). 1 mg of pMyc-LRRK2, pHA-CHIP and pFlag-Hsp90 were co-transfected into
1.5610
7 HEK293 cells in 100 mm dishes. Lacatcystin was added at 5 mM to prevent CHIP-mediated degradation of LRRK2. The cells were incubated
for 48 hours and the cell lysate was subjected to immunoprecipitatiom using a polyclonal anti-myc antibody or rabbit IgG. The immunoprecipitants
and their cell lysates were probed with monoclonal anti-HA, anti-Flag and anti-myc antibodies. (B). 3 mg of pMyc-LRRK2 was transfected into 1.5610
7
HEK293 cells in 100 mm dishes. The cells were incubated for 48 hours and the cell lysate was subject to immunoprecipitation using polyclonal anti-
myc antibody or rabbit IgG. The immunoprecipitants were probed using anti-CHIP or anti-Hsp90 antibodies. (C) Model of LRRK2 binding to CHIP and
Hsp90. CHIP can form a stable complex with LRRK2 by at least two independent protein-protein interactions. The N-terminal TPR domain of CHIP can
bind to the N-terminal ARM domain of LRRK2 indirectly via Hsp90. The intermediate charged domain of CHIP can bind to the ROC domain of LRRK2
independent of Hsp90. The U-box domain of CHIP is dispensable for binding to LRRK2 but required for CHIP-mediated ubiquitination and
proteasome-dependent degradation of LRRK2.
doi:10.1371/journal.pone.0005949.g007
CHIP Regulates LRRK2 Stability
PLoS ONE | www.plosone.org 12 June 2009 | Volume 4 | Issue 6 | e5949Hsp90 can also bind to the ARM domain at the N-terminus of
LRRK2. ARM domains mediate protein-protein interactions and
are found in proteins with diverse functions including cytoskeletal
regulation and intracellular signaling [50]. Here we propose a model
in which the ARM domain stabilizes LRRK2 in part by binding to
Hsp90 (Figure 7C). Because the TPR domain of CHIP is well-known
to bind to Hsp90 [35], it is likely that a portion of the LRRK2-Hsp90
complex will also be associated with CHIP. LRRK2 apparently
forms a stable complex with Hsp90 and CHIP because we
successfully immunoprecipitated endogenous CHIP and endogenous
Hsp90 together with LRRK2 (Figure 7).
Our data (Figure 6) confirm that overexpression of Hsp90
stabilizes LRRK2 and that inhibition of endogenous Hsp90 by
geldanamycin destabilizes LRRK2, as previously reported [27].
Importantly, we show for the first time that Hsp90 overexpression
impairs CHIP-mediated degradation of LRRK2 (Figure 6A) and
that inhibition of endogenous Hsp90 by geldanamycin enhances
CHIP-mediated degradation of LRRK2 (Figure 6B). According to
our model (Figure 7C), inhibition of endogenous Hsp90 by
geldanamycin prevents CHIP binding to the N-terminal half of
LRRK2 (Figure 2G) but does not inhibit the Hsp90-independent
binding of CHIP to the C-terminal half of LRRK2 (including the
ROC domain), which promotes the ubiquitination and protea-
some-dependent degradation of LRRK2. In the presence of excess
CHIP, Hsp90-dependent binding of CHIP to the ARM domain of
LRRK2 can also destabilize LRRK2. We hypothesize that the
stability of LRRK2 depends on the ratio of the cellular abundance
and binding availability of Hsp90 and CHIP.
The fact that LRRK2 mutations cause both familial and
apparently sporadic forms of PD with typical clinical symptoms
and late age-at-onset [51] highlights the significance of age as a
causative factor for both familial and idiopathic PD. An important
question is whether the cellular abundance and binding availabil-
ity of Hsp90 and CHIP change with age and whether this
contributes to PD risk, perhaps by increasing LRRK2 abundance,
aggregation or neurotoxicity. It has been proposed that the ability
of CHIP to degrade potentially neurotoxic misfolded, damaged or
mutated proteins might diminish with age [25]. Our findings raise
the possibility that diminished CHIP-mediated degradation of
LRRK2 in aged or stressed neurons may contribute to sporadic
PD as well as familial PD in patients bearing LRRK2 mutations.
Further studies of the detailed mechanisms that control LRRK2
levels may lead to the development of PD therapies that exploit
these mechanisms to degrade wild-type or mutant LRRK2 and
thereby mitigate neurotoxicity.
Supporting Information
Figure S1 Diagrams of LRRK2 and CHIP constructs used for
experimental analyses. The domains of LRRK2 and CHIP are
shown as labeled boxes. The locations of all the individual amino
acid point mutations or variants used for analyses are shown in full
length LRRK2 and full length CHIP, although each construct
used for experimental analysis was either wild-type or mutated at a
single site. Myc epitope tags were used for all constructs expressing
full length or partial fragments of LRRK2. HA epitope tags were
used for all constructs expressing full length or partial fragments of
CHIP. Abreviations: ARM, armadillo repeat domain of LRRK2;
ANK, ankyrin repeat domain of LRRK2; LRR, leucine-rich
repeat domain of LRRK2; ROC, Ras of complex domain of
LRRK2; COR, C-terminal of Roc domain of LRRK2; Kinase,
kinase domain of LRRK2; WD40, WD40 domain of LRRK2;
TPR, tetratricopeptide repeat domain of CHIP; CD, charged
domain of CHIP; U-box, U-box domain of CHIP.
Found at: doi:10.1371/journal.pone.0005949.s001 (0.37 MB EPS)
Figure S2 The TPR domain of CHIP is sufficient to bind to the
N-terminal portion of LRRK2 and the K30A point mutation that
disrupts CHIP binding to Hsp90 disrupts CHIP binding to the N-
terminal portion of LRRK2 but not to the C-terminal portion of
LRRK2. The indicated constructs (0.5 mg for each) were co-
transfected into 4.5610
6 HEK293 cells in 60 mm dishes. HEK293
cell lysates were subjected to immunoprecipitation using poly-
clonal anti-myc or anti-HA antibodies, then immunoblotted using
monoclonal anti-HA or anti-myc antibodies, respectively. Cell
lysates were also directly immunoblotted using monoclonal anti-
HA and anti-myc antibodies to verify similar protein expression
levels in experimental and empty expression vector (CMV) control
transfections. (A) Co-immunoprecipitation of isolated CHIP TPR
domain and the ARM-Ankyrin-LRR (AAL) portion of LRRK2;
(B) Absence of co-immunoprecipitation of isolated CHIP TPR
domain and the ROC-COR-Kinase-WD40 (RCKW) portion of
LRRK2; (C) Absence of co-immunoprecipitation of K30A point
mutant CHIP TPR domain and the ARM-Ankyrin-LRR (AAL)
portion of LRRK2; (D) Absence of co-immunoprecipitation of
K30A point mutant CHIP TPR domain and the ROC-COR-
Kinase-WD40 (RCKW) portion of LRRK2; (E) Co-immunopre-
cipitation of isolated CHIP TPR domain and full length LRRK2;
(F) Absence of co-immunoprecipitation of K30A point mutant full
length CHIP and full length LRRK2; (G) Absence of co-
immunoprecipitation of K30A point mutant full length CHIP
and the ARM-Ankyrin-LRR (AAL) portion of LRRK2; (H) Co-
immunoprecipitation of K30A point mutant full length CHIP and
the ROC-COR-Kinase-WD40 (RCKW) portion of LRRK2.
Found at: doi:10.1371/journal.pone.0005949.s002 (2.31 MB EPS)
Figure S3 Geldanamycin does not impair the association of full
length CHIP with full length LRRK2. The indicated constructs
(0.5 mg for each) were co-transfected into 4.5610
6 HEK293 cells
in 60 mm dishes. Geldanamycin was added into the medium to
1 mM final concentration and incubated for 1 hour prior to cell
collection. HEK293 cell lysates were subjected to immunoprecip-
itation using polyclonal anti-myc or anti-HA antibodies, then
immunoblotted using monoclonal anti-HA or anti-myc antibodies,
respectively. Cell lysates were also directly immunoblotted using
monoclonal anti-HA and anti-myc antibodies to verify similar
protein expression levels in experimental and empty expression
vector (CMV) control transfections.
Found at: doi:10.1371/journal.pone.0005949.s003 (0.49 MB EPS)
Figure S4 CHIP binds to wild-type, G2019S, R1441C and
D1994A LRRK2. The indicated constructs (0.5 mg for each) were
co-transfected into 4.5610
6 HEK293 cells in 60 mm dishes.
HEK293 cell lysates were subjected to immunoprecipitation using
polyclonal anti-myc or anti-HA antibodies, then immunoblotted
using monoclonal anti-HA or anti-mycantibodies, respectively. Cell
lysates were also directly immunoblotted using monoclonal anti-HA
and anti-myc antibodies to verify similar protein expression levels in
experimental and empty expression vector (CMV) control trans-
fections. (A) Co-immunoprecipitation of full-length CHIP and full
length wild-type LRRK2; (B) Co-immunoprecipitation of CHIP
and G2019S mutant LRRK2. (C) Co-immunoprecipitation of
CHIP and R1441C mutant LRRK2. (D) Co-immunoprecipitation
of CHIP and D1994A variant LRRK2.
Found at: doi:10.1371/journal.pone.0005949.s004 (1.00 MB EPS)
Figure S5 CHIP siRNA stabilizes LRRK2. (A). 0.05 mgo f
pMyc-LRRK2 was co-transfected with 0-40 picomoles of CHIP
siRNA into 1.5610
5 neuroblastoma SH-SY5Y cells in 24-well
format. After 48-hour incubation, the cells were harvested and the
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Parallel cells were similarly co-transfected using 0.05 mg of pMyc-
LRRK2 and 0–40 picomoles of non-targeting siRNA in place of
CHIP siRNA and western blotted to confirm no effects on the
levels of endogenous CHIP or transfected Myc-LRRK2.
Found at: doi:10.1371/journal.pone.0005949.s005 (0.71 MB EPS)
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